JP7489397B2 - Ｒ－ｃｈｏｐとの組み合わせ及び複合薬におけるチダミドの適用 - Google Patents

Ｒ－ｃｈｏｐとの組み合わせ及び複合薬におけるチダミドの適用 Download PDF

Info

Publication number
JP7489397B2
JP7489397B2 JP2021551329A JP2021551329A JP7489397B2 JP 7489397 B2 JP7489397 B2 JP 7489397B2 JP 2021551329 A JP2021551329 A JP 2021551329A JP 2021551329 A JP2021551329 A JP 2021551329A JP 7489397 B2 JP7489397 B2 JP 7489397B2
Authority
JP
Japan
Prior art keywords
combination
cell lymphoma
chidamide
chop
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021551329A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511126A (ja
JP2022511126A5 (enExample
Inventor
ルー、シエンビン
チャオ、ウェイリー
フー、シン
シュー、ペンペン
リュー、ティン
Original Assignee
シェンチェン チップスクリーン バイオサイエンシズ カンパニー、リミテッド
ルイ ジン ホスピタル アフィリエイテッド トゥー シャンハイ ジャオ トン ユニバーシティー スクール オブ メディスン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シェンチェン チップスクリーン バイオサイエンシズ カンパニー、リミテッド, ルイ ジン ホスピタル アフィリエイテッド トゥー シャンハイ ジャオ トン ユニバーシティー スクール オブ メディスン filed Critical シェンチェン チップスクリーン バイオサイエンシズ カンパニー、リミテッド
Publication of JP2022511126A publication Critical patent/JP2022511126A/ja
Publication of JP2022511126A5 publication Critical patent/JP2022511126A5/ja
Application granted granted Critical
Publication of JP7489397B2 publication Critical patent/JP7489397B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021551329A 2018-11-20 2019-11-18 Ｒ－ｃｈｏｐとの組み合わせ及び複合薬におけるチダミドの適用 Active JP7489397B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811394614.7 2018-11-20
CN201811394614 2018-11-20
PCT/CN2019/119170 WO2020103788A1 (zh) 2018-11-20 2019-11-18 西达本胺联合r-chop的应用及联合药物

Publications (3)

Publication Number Publication Date
JP2022511126A JP2022511126A (ja) 2022-01-28
JP2022511126A5 JP2022511126A5 (enExample) 2022-08-24
JP7489397B2 true JP7489397B2 (ja) 2024-05-23

Family

ID=70741744

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021551329A Active JP7489397B2 (ja) 2018-11-20 2019-11-18 Ｒ－ｃｈｏｐとの組み合わせ及び複合薬におけるチダミドの適用

Country Status (12)

Country Link
US (1) US12194054B2 (enExample)
EP (1) EP3884943B1 (enExample)
JP (1) JP7489397B2 (enExample)
KR (1) KR102958344B1 (enExample)
CN (2) CN111195249B (enExample)
AU (1) AU2019385373B2 (enExample)
BR (1) BR112021009627A2 (enExample)
MY (1) MY209036A (enExample)
PH (1) PH12021551138A1 (enExample)
SG (1) SG11202105137RA (enExample)
TW (1) TWI768263B (enExample)
WO (1) WO2020103788A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113813268A (zh) * 2020-06-18 2021-12-21 苏州亚盛药业有限公司 包含Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂的组合产品及其用途
CN112274509B (zh) * 2020-12-02 2022-04-26 四川大学华西医院 西达本胺联合bcl2抑制剂在双表达型b细胞淋巴瘤中的应用
CN118593502B (zh) * 2024-05-24 2026-08-04 厦门大学附属第一医院 一种预防或治疗tp53突变双打击淋巴瘤的联合用药物组合物及其应用
CN121513004B (zh) * 2026-01-14 2026-04-03 首都医科大学附属北京友谊医院 一种治疗abc型弥漫性大b细胞淋巴瘤的组合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018017858A1 (en) 2016-07-20 2018-01-25 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and compositions and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1974747E (pt) * 1998-08-11 2012-09-05 Biogen Idec Inc Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20
HRP20060080A2 (en) * 2003-08-26 2006-07-31 Sloan-Kettering Institute For Cancer Research Method of treating cancer with hdac inhibitors
CN101146548A (zh) * 2005-02-15 2008-03-19 诺华疫苗和诊断公司 化疗药、il-2和任选的抗cd20抗体联用治疗淋巴瘤的方法
CN101470112A (zh) * 2007-12-28 2009-07-01 上海交通大学医学院附属瑞金医院 弥漫性大b细胞淋巴瘤治疗指导和预后判断的分子标志物
CN103833626B (zh) 2012-11-27 2015-11-25 深圳微芯生物科技有限责任公司 西达本胺的晶型及其制备方法与应用
TWI808055B (zh) * 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CN107157978B (zh) * 2017-05-24 2021-06-18 中国药科大学 治疗ebv+dlbcl和dlbcl的药物及组合物
CN108743947B (zh) * 2018-07-04 2020-12-15 复旦大学附属肿瘤医院 一种治疗b细胞淋巴瘤的药物组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018017858A1 (en) 2016-07-20 2018-01-25 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and compositions and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XU, P., et al.，Blood，2017年，Vol.130, Suppl_1，p.4126.

Also Published As

Publication number Publication date
TW202033194A (zh) 2020-09-16
AU2019385373B2 (en) 2025-08-21
SG11202105137RA (en) 2021-06-29
CN111195249B (zh) 2023-11-28
KR20210104059A (ko) 2021-08-24
CA3120207A1 (en) 2020-05-28
US12194054B2 (en) 2025-01-14
JP2022511126A (ja) 2022-01-28
CN111195249A (zh) 2020-05-26
US20220016147A1 (en) 2022-01-20
EP3884943B1 (en) 2024-07-17
PH12021551138A1 (en) 2022-02-21
EP3884943A1 (en) 2021-09-29
EP3884943A4 (en) 2022-07-06
BR112021009627A2 (pt) 2021-08-10
MY209036A (en) 2025-06-17
CN117797149A (zh) 2024-04-02
WO2020103788A1 (zh) 2020-05-28
KR102958344B1 (ko) 2026-04-29
TWI768263B (zh) 2022-06-21
AU2019385373A1 (en) 2021-06-24
EP3884943C0 (en) 2024-07-17

Similar Documents

Publication Publication Date Title
KR102958344B1 (ko) R-chop와 병용되는 치다마이드의 활용 및 약물 조합
AU2012321110B2 (en) Combination treatment
Wang et al. PEG-G-CSF and L-citrulline combination therapy for mitigating skin wound combined radiation injury in a mouse model
CN113908159A (zh) 西奥罗尼及其联合用药治疗非霍奇金淋巴瘤的用途
Pelosi et al. The growing role of the BH3 mimetic drug venetoclax in the therapy of acute myeloid leukemia
CA3120207C (en) Application of chidamide in combination with r-chop, and drug combination
JP2012031141A (ja) 骨髄異形性症候群を治療するための組成物および方法
RU2802620C2 (ru) Применение хидамида в комбинации с R-CHOP и комбинация лекарственных средств
CN111228264A (zh) 西达本胺联合cgb以及自体造血干细胞的应用及联合药物
HK40057612A (en) Application of chidamide in combination with r-chop, and drug combination
HK40057612B (en) Application of chidamide in combination with r-chop, and drug combination
CN111195250A (zh) 西达本胺联合dice的应用及联合药物
JP2012025734A (ja) 骨髄異形性症候群を治療するための組成物および方法
JP2022541173A (ja) リゾチームを含む医薬組成物およびその使用
CN119405643B (zh) 曲尼斯特的用途
KR102830916B1 (ko) 카르니틴 아실카르니틴 운반자 억제제 및 카르니틴 옥타노일트랜스퍼라제 억제제를 포함하는 암 예방 또는 치료용 약학적 조성물
KR20130020945A (ko) 골수이형성 증후군을 치료하기 위한 조성물 및 방법
KR20130020944A (ko) 골수이형성 증후군을 치료하기 위한 조성물 및 방법
MX2011009301A (es) Composiciones y metodos para tratar sindrome mielodisplasico.
WO2013019222A1 (en) Compositions and methods for treating myelodysplastic syndrome
WO2016090316A1 (en) Composition and method for treating bipolar disorder
TW201306831A (zh) 用於治療骨髓發育不良症候群的組成物及方法
Kochi et al. Efficacy of low-dose thiopurine therapy for the induction of remission in steroid-dependent ulcerative colitis: Comparison with cytapheresis
HK1162149A (en) Compositions for use in treating myelodysplastic syndrome
WO2013019220A1 (en) Compositions and methods for treating myelodysplastic syndrome

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220815

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220815

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231010

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240318

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240424

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240513

R150 Certificate of patent or registration of utility model

Ref document number: 7489397

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150